Aurélie Cabannes-Hamy

Aurélie Cabannes-Hamy

Auto-generated profile, based on publicly available information

Aurélie Cabannes-Hamy

Hematology Centre Hospitalier de Versailles Site André Mignot Le Chesnay‐Rocquencourt France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CCCharlotte Calvo
Charlotte Calvo
ACAurélie Cabannes‐Hamy
Aurélie Cabannes‐Hamy
DADalila Adjaoud
Dalila Adjaoud
BBBénédicte Bruno
Bénédicte Bruno
LBLaurence Blanc
Laurence Blanc
BBBenoit Brethon
Benoit Brethon
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

22 March 2025 in European Journal of Cancer
Verified
Journal Article
Open access
LRLoïc Renaud
Loïc Renaud
MDMarie Donzel
Marie Donzel
JDJustine Decroocq
Justine Decroocq
PDPierre Decazes
Pierre Decazes
JGJean Galtier
Jean Galtier
Vincent CamusVincent Camus
Vincent Camus
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled with improvements in diagnostic tools and therapeutic approaches, have significantly improved patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the Lymphoma Study Association (LYSA) for the management of PMBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. The aim of the guidelines is to provide clinicians with a clear, practical framework to optimize care for patients with PMBCL, ensuring that the best available evidence is translated into clinical practice.

8 November 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
ACAurélie Cabannes‐Hamy
Aurélie Cabannes‐Hamy
NBNicolas Boissel
Nicolas Boissel
RLRégis Peffault De Latour
Régis Peffault De Latour
ELEtienne Lengliné
Etienne Lengliné
TLThierry Leblanc
Thierry Leblanc
NDNathalie Dhédin
Nathalie Dhédin
Summary: The incidence of acquired aplastic anaemia (AA) peaks in adolescents and young adults (AYA). Although age has been associated with response after immunosuppressive therapy (IST), few data exist about the specific outcome of AYA. We retrospectively compared the outcome of 29 children (aged <15 years), 32 AYA (15–25 years) and 23 adults (>25 years) with AA treated front‐line with IST in Saint‐Louis Hospital. The cumulative incidence of response was lower in adults compared with AYA (subdistribution hazard ratio [SHR] = 0·38, 95% confidence interval [CI] [0·96–1·00], P = 0·008), but no difference was observed between children and AYA (SHR = 0·84, 95% CI [0·96–1·00], P = 0·56), with a 6 months cumulative incidence of partial response of 44·8% in children, 62·5% in AYA and 21·7% in adults. The 5‐year failure‐free survival was 48·4%, without impact of age, with a 5‐year relapse rate of 20·7%. With a median follow‐up of 5·4 years, the 5‐year overall survival was 86·5%, without significant difference between children and AYA overall survival (hazard ratio [HR] 1·51, 95% CI [0·25–9·02], P = 0·66), while adults displayed poorer survival than AYA (HR 4·98, 95% CI [1·00–24·73], P = 0·049). This study confirms that age is a prognostic factor in AA patients treated with IST. However, AYA patients have a similar outcome to children in terms of response rate and survival.

27 October 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
APAntoine Pinton
Antoine Pinton
LCLucien Courtois
Lucien Courtois
CDCharlotte Doublet
Charlotte Doublet
ACAurélie Cabannes-Hamy
Aurélie Cabannes-Hamy
GAGuillaume Andrieu
Guillaume Andrieu
VAVahid Asnafi
Vahid Asnafi
Purpose: To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL). Experimental Design: We described PHF6 alterations in an adult cohort of T-ALL from the French trial Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 and retrospectively analyzed clinical outcomes between PHF6-altered (PHF6ALT) and wild-type patients. We also used EPIC and chromatin immunoprecipitation sequencing data of patient samples to analyze the epigenetic landscape of PHF6ALT T-ALLs. We consecutively evaluated 5-azacitidine efficacy, alone or combined with venetoclax, in PHF6ALT T-ALL. Results: We show that PHF6 alterations account for 47% of cases in our cohort and demonstrate that PHF6ALT T-ALL presented significantly better clinical outcomes. Integrative analysis of DNA methylation and histone marks shows that PHF6ALT are characterized by DNA hypermethylation and H3K27me3 loss at promoters physiologically bivalent in thymocytes. Using patient-derived xenografts, we show that PHF6ALT T-ALL respond to the 5-azacytidine alone. Finally, synergism with the BCL2-inhibitor venetoclax was demonstrated in refractory/relapsing (R/R) PHF6ALT T-ALL using fresh samples. Importantly, we report three cases of R/R PHF6ALT patients who were successfully treated with this combination. Conclusions: Overall, our study supports the use of PHF6 alterations as a biomarker of sensitivity to 5-azacytidine and venetoclax combination in R/R T-ALL.

23 February 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ACAurélie Cabannes‐Hamy
Aurélie Cabannes‐Hamy
FPFrederic Peyrade
Frederic Peyrade
FJFabrice Jardin
Fabrice Jardin
JEJean‐François Emile
Jean‐François Emile
VDVincent Delwail
Vincent Delwail
TAthe lymphoma study association
the lymphoma study association
CNS relapse is reported in 2–5% of diffuse large B‐cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03‐7B, LNH09‐7B) evaluating the addition of rituximab or ofatumumab to mini‐CHOP as front‐line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and survival. Median age was 83 years (range: 79–95). After a median follow‐up of 28.7 months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2 months (range: 3.2–32.6). Patients survived a median of 1.5 months after CNS relapse (range: 0.4–4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 0.4–3.5) compared to patients with non‐CNS relapse (6.6 months; 95% CI: 4.6–11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients with CNS disease did not differ significantly between patients with low‐intermediate risk according to CNS‐IPI and patients with high risk (3% vs. 2.8%, P = 1.00). CNS relapse cumulative incidence in very elderly treatment‐naive patients is 1.8% at 2 years and is associated with poor survival. This population had a long median time to CNS relapse. Absence of prophylaxis did not strongly impact CNS relapse incidence.

29 May 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ACAurélie Cabannes‐Hamy
Aurélie Cabannes‐Hamy
RKRayan Kabirian
Rayan Kabirian
FJFloriane Jochum
Floriane Jochum
KBKevin Bihan
Kevin Bihan
EDElise Dumas
Elise Dumas
PGPaul Gougis
Paul Gougis
Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to investigate pregnancy and fetal/newborn adverse outcomes resulting from exposure to BCR::ABL1‐TKIs during pregnancy. For this disproportionality analysis, we used the WHO's global VigiBase up to January 2024, and included reports involving pregnancy, antineoplastic treatment during pregnancy, and cancer. The exposure group consisted of reports mentioning BCR::ABL1‐TKIs at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal‐fetal complications in the BCR::ABL1‐TKIs group compared to other anticancer treatments. The analysis included 3,389 reports (TKI = 969; other = 2,420). In the BCR::ABL1‐TKI‐exposed group, the mean age was 28.9 years, and 724 patients (92.2%) were treated for CML. BCR::ABL1‐TKIs were mainly imatinib (n = 642, 66.3%), nilotinib (n = 218, 22.5%), and dasatinib (n = 127, 13.1%) reported without other non‐TKI anticancer agents(92.3%). Compared to other anticancer drugs, overreported outcomes with TKIs included hydrops fetalis (ROR = 13 [95%CI = 1.5–110], P = 0.009), polyhydramnios (ROR = 5 [1.3–20], P = 0.02), and threatened preterm labor (ROR = 10 [1.1–90], P = 0.03). When analyzing specific molecule effects, hydrops fetalis (ROR = 27 [5.4–130], P = 0.001) and polyhydramnios (ROR = 13 [3.3–54], P = 0.004) were overreported with dasatinib. In this large cohort of 969 individuals exposed to TKIs during pregnancy, dasatinib use was associated with most BCR::ABL1‐TKI‐specific toxicities and should be avoided during pregnancy. Fewer or no adverse events were overreported with imatinib and nilotinib.